1. After successful treatment of the blood-stage infection, patients with Plasmodium vivax or Plasmodium ovale malaria can relapse weeks to months later. This is because these two species form hypnozoites — dormant parasite forms that persist in liver cells (hepatocytes) and are not killed by drugs that act only on parasites inside red blood cells. Which statement correctly describes the clinical significance of hypnozoites?
A) Hypnozoites circulate in the bloodstream and are responsible for the cyclical fevers of acute malaria
B) Hypnozoites are the sexual forms taken up by mosquitoes and are the basis of disease transmission
C) Hypnozoites are dormant liver-stage forms that cause relapse and are eliminated only by 8-aminoquinoline drugs such as primaquine and tafenoquine
D) Hypnozoites are produced by all four human Plasmodium species and explain relapse in falciparum malaria
E) Hypnozoites are eradicated by standard blood-stage drugs such as chloroquine, so relapse reflects reinfection rather than dormant parasites
ANSWER: C
Rationale:
Hypnozoites are the dormant hepatic (liver-stage) forms unique to Plasmodium vivax and Plasmodium ovale. They remain quiescent in hepatocytes after the initial infection and reactivate weeks to months later, producing a relapse of blood-stage disease. Because blood-stage drugs (blood schizonticides) never reach this dormant liver reservoir, eradicating hypnozoites — called radical cure — requires an 8-aminoquinoline (primaquine for a multiday course, or single-dose tafenoquine). Option C correctly captures both the location/behavior of hypnozoites and the drug class required to eliminate them.
Option A: Option A is incorrect because the cyclical fevers of acute malaria are produced by synchronized rupture of infected erythrocytes during the blood stage, not by hypnozoites, which are dormant and non-replicating in the liver.
Option B: Option B is incorrect because it describes gametocytes (the sexual forms ingested by the mosquito), not hypnozoites.
Option D: Option D is incorrect because only P. vivax and P. ovale form hypnozoites; P. falciparum and P. malariae do not, and falciparum does not cause true hypnozoite-mediated relapse.
Option E: Option E is incorrect because standard blood-stage drugs such as chloroquine have no activity against hypnozoites, which is precisely why relapse occurs unless an 8-aminoquinoline is added.
2. Inside the red blood cell, the malaria parasite digests hemoglobin and releases free heme, which is toxic to the parasite. The parasite normally protects itself by polymerizing free heme into an inert, insoluble crystal called hemozoin (malaria pigment). Chloroquine is a 4-aminoquinoline that concentrates in the parasite's acidic digestive vacuole, the compartment where this process occurs. What is the mechanism by which chloroquine kills the parasite?
A) It binds free heme and blocks its polymerization into hemozoin, so toxic free heme accumulates and destroys the parasite
B) It inhibits the parasite enzyme dihydrofolate reductase, halting folate synthesis and DNA replication
C) It generates reactive oxygen species inside parasite mitochondria, causing oxidative damage
D) It blocks the parasite electron transport chain by inhibiting cytochrome bc1
E) It inhibits parasite protein synthesis by binding the parasite ribosome
ANSWER: A
Rationale:
Chloroquine concentrates within the acidic digestive vacuole of the intraerythrocytic parasite, where hemoglobin is catabolized and free heme (ferriprotoporphyrin IX) is liberated. Free heme is toxic, and the parasite survives by polymerizing it into inert hemozoin. Chloroquine binds free heme and prevents this polymerization step, so toxic free heme and chloroquine-heme complexes accumulate, disrupt vacuolar membrane integrity, and kill the parasite. This is the correct mechanism.
Option B: Option B is incorrect because dihydrofolate reductase inhibition describes the antifolate agents (for example pyrimethamine), not chloroquine.
Option C: Option C is incorrect because reactive-oxygen generation in parasite mitochondria is the proposed mechanism of the 8-aminoquinolines (primaquine, tafenoquine), not chloroquine.
Option D: Option D is incorrect because cytochrome bc1 (electron transport chain) inhibition is the mechanism of atovaquone, not chloroquine.
Option E: Option E is incorrect because parasite protein-synthesis inhibition via the ribosome describes antibiotics used as antimalarials (for example doxycycline, clindamycin), not chloroquine.
3. Artemisinin-based combination therapy (ACT) is the recommended first-line treatment for uncomplicated Plasmodium falciparum malaria worldwide. The word "combination" is central to how these regimens are designed. Which statement best describes the rationale for the two-drug structure of an ACT?
A) Two artemisinin derivatives are combined so that a missed dose of one is covered by the other
B) An artemisinin derivative is combined with a second artemisinin given by a different route to ensure absorption
C) Two slow-acting partner drugs are combined because neither is effective alone
D) A fast-acting artemisinin derivative rapidly reduces parasite burden, while a longer-acting partner drug clears the remaining parasites and protects the short-lived artemisinin from resistance
E) An artemisinin derivative is combined with a drug that has no antimalarial activity but slows artemisinin metabolism
ANSWER: D
Rationale:
Artemisinin derivatives act extremely rapidly and produce the fastest parasite killing of any antimalarial class, but they have a very short half-life, so a few days of artemisinin alone would leave surviving parasites and select for resistance. ACTs therefore pair the fast-acting, short-lived artemisinin with a structurally unrelated, longer-acting partner drug (for example lumefantrine, mefloquine, or piperaquine): the artemisinin rapidly collapses the parasite burden, and the partner drug remains present to eliminate residual parasites and shield the artemisinin component from resistance selection. Option D captures this complementary-kinetics rationale.
Option A: Option A is incorrect because ACTs do not pair two artemisinins; the second agent is a different, longer-acting class.
Option B: Option B is incorrect for the same reason and because the design is about pharmacokinetic complementarity, not route of administration.
Option C: Option C is incorrect because the artemisinin component is fast-acting, not slow, and is highly effective at reducing parasite burden.
Option E: Option E is incorrect because the partner drug is itself an active antimalarial that clears residual parasites; it is not a pharmacokinetic booster devoid of antimalarial activity.
4. Before prescribing primaquine or tafenoquine (the 8-aminoquinoline drugs used to prevent relapse of vivax and ovale malaria), a specific laboratory test must be performed. These drugs generate oxidative stress inside red blood cells. Which test is required before use, and why?
A) An electrocardiogram, because 8-aminoquinolines characteristically prolong the QT interval and cause arrhythmia
B) A glucose-6-phosphate dehydrogenase (G6PD) level, because patients deficient in this red-cell antioxidant enzyme develop dose-dependent hemolytic anemia
C) A baseline retinal examination, because 8-aminoquinolines deposit in the retina and cause vision loss
D) Liver function tests, because 8-aminoquinolines commonly cause fulminant hepatic failure
E) A pregnancy test only, because the sole contraindication to these drugs is pregnancy
ANSWER: B
Rationale:
Glucose-6-phosphate dehydrogenase (G6PD) is the enzyme that regenerates the reduced glutathione red blood cells need to defend against oxidative stress. The 8-aminoquinolines (primaquine, tafenoquine) generate oxidative metabolites; in a G6PD-deficient patient, red cells cannot neutralize this stress and undergo dose-dependent hemolysis that can be severe or life-threatening depending on the variant. A quantitative G6PD level is therefore mandatory before these drugs are given. Option B is correct.
Option A: Option A is incorrect because clinically important QT prolongation is associated with quinine, quinidine, and some ACT partner drugs, not the 8-aminoquinolines, and an electrocardiogram is not the required pre-treatment screen here.
Option C: Option C is incorrect because retinal deposition and vision loss are concerns of long-term chloroquine and hydroxychloroquine use, not of 8-aminoquinolines.
Option D: Option D is incorrect because fulminant hepatic failure is not the characteristic 8-aminoquinoline toxicity; the defining risk is oxidative hemolysis in G6PD deficiency.
Option E: Option E is incorrect because, although these drugs are avoided in pregnancy (fetal G6PD status is unknown), the specific required pre-treatment test is the G6PD level, not a pregnancy test alone.
5. Mefloquine is an effective once-weekly malaria prophylaxis drug, but it carries a boxed warning (the strongest warning a drug label can carry) for a specific category of adverse effect. A traveler asks why this drug is not appropriate for everyone. Which adverse effect profile explains the boxed warning and the resulting contraindication?
A) Severe oxidative hemolysis, contraindicating use in anyone with G6PD enzyme deficiency
B) Irreversible retinal toxicity, contraindicating use in anyone with pre-existing eye disease
C) Profound QT prolongation, contraindicating use in anyone with structural heart disease
D) Fulminant hepatotoxicity, contraindicating use in anyone with chronic liver disease
E) Neuropsychiatric effects — vivid dreams, anxiety, and in some patients psychosis or seizures — contraindicating use in anyone with a history of psychiatric disorders or seizures
ANSWER: E
Rationale:
Mefloquine's boxed warning concerns neuropsychiatric toxicity. At prophylactic doses a substantial minority of users experience vivid or disturbing dreams, sleep disturbance, anxiety, and dizziness, and a smaller proportion develop frank psychosis, seizures, or prolonged neuropsychiatric sequelae. Because of this, mefloquine is contraindicated in patients with a history of psychiatric disorders (including depression and anxiety) or seizures, and it should be started in advance of travel so intolerance can be detected before reaching a remote destination. This is correct.
Option A: Option A is incorrect because oxidative hemolysis in G6PD deficiency is the signature risk of the 8-aminoquinolines, not mefloquine.
Option B: Option B is incorrect because retinal toxicity is associated with long-term chloroquine and hydroxychloroquine, not mefloquine.
Option C: Option C is incorrect because pronounced QT prolongation is characteristic of quinine and quinidine; mefloquine's defining boxed-warning risk is neuropsychiatric, not cardiac.
Option D: Option D is incorrect because fulminant hepatotoxicity is not mefloquine's characteristic or boxed-warning toxicity.
6. Four species of the malaria parasite Plasmodium classically infect humans: P. falciparum, P. vivax, P. ovale, and P. malariae. A clinician evaluating a febrile returning traveler needs to know which species is the priority concern. Which statement is correct?
A) Plasmodium falciparum causes the most severe and potentially fatal disease, including cerebral malaria, and is the priority to identify and treat
B) Plasmodium malariae is the most lethal species and the leading cause of malaria deaths worldwide
C) All four species cause identical clinical disease, so species identification has no effect on management
D) Plasmodium ovale is the most common cause of severe malaria requiring intravenous therapy
E) Plasmodium vivax cannot cause symptomatic illness and is detected only incidentally
ANSWER: A
Rationale:
Among the human malaria species, Plasmodium falciparum causes the most severe disease and the great majority of malaria deaths, because it can infect erythrocytes of all ages, reach very high parasite densities, and sequester in the microvasculature, producing complications such as cerebral malaria, severe anemia, and multiorgan failure. Identifying falciparum is therefore the priority in a febrile traveler. Option A is correct.
Option B: Option B is incorrect because P. malariae generally causes a mild, chronic, low-grade infection and is not a major cause of death.
Option C: Option C is incorrect because species identification directly changes management — for example, vivax and ovale require an 8-aminoquinoline for radical cure, and falciparum requires prompt artemisinin-based combination therapy.
Option D: Option D is incorrect because P. ovale causes a relatively mild relapsing illness, not the predominant form of severe malaria.
Option E: Option E is incorrect because P. vivax causes substantial symptomatic, debilitating, and relapsing illness.
7. Artemisinin and its derivatives contain an unusual chemical feature: an endoperoxide bridge (a reactive oxygen-oxygen bond within the molecule). This structural feature is essential to how the drug kills the parasite. Which statement correctly describes how the endoperoxide bridge produces antimalarial activity?
A) The endoperoxide bridge binds the parasite ribosome and halts protein synthesis
B) The endoperoxide bridge inhibits the folate-synthesis enzyme dihydropteroate synthase
C) The endoperoxide bridge is cleaved by parasite-derived heme iron, generating reactive free radicals that damage parasite proteins and membranes
D) The endoperoxide bridge blocks the parasite chloroquine resistance transporter, restoring chloroquine activity
E) The endoperoxide bridge chelates calcium, depleting an ion the parasite requires for invasion
ANSWER: C
Rationale:
The antimalarial potency of artemisinins depends on the endoperoxide (peroxide) bridge. Within the parasite, the iron released from heme during hemoglobin digestion cleaves this bridge, generating carbon-centered free radicals and reactive oxygen species that alkylate and damage parasite proteins, lipids, and membranes, killing the parasite rapidly. This heme-iron dependence also explains why artemisinins act most strongly on the metabolically active blood stages that are actively digesting hemoglobin. Option C is correct.
Option A: Option A is incorrect because ribosomal protein-synthesis inhibition describes antibiotic antimalarials such as doxycycline, not artemisinins.
Option B: Option B is incorrect because dihydropteroate synthase inhibition is the mechanism of the sulfonamide antifolates (for example sulfadoxine), not artemisinins.
Option D: Option D is incorrect because artemisinins do not act by reversing the chloroquine resistance transporter.
Option E: Option E is incorrect because artemisinin activity is driven by radical generation from endoperoxide cleavage, not by calcium chelation.
8. Quinine is the oldest antimalarial drug still in use, with a history spanning centuries. Which statement correctly identifies its natural origin and its principal antimalarial action?
A) Quinine is a synthetic 8-aminoquinoline whose main action is eradicating dormant liver hypnozoites
B) Quinine is the natural alkaloid of Cinchona tree bark and acts as a blood schizonticide, killing parasites in the erythrocytic (red blood cell) stage
C) Quinine is a recombinant protein that acts as a transmission-blocking vaccine
D) Quinine is an antibiotic derived from soil bacteria and acts only by inhibiting the parasite ribosome
E) Quinine is a synthetic endoperoxide and acts only on dormant liver-stage parasites
ANSWER: B
Rationale:
Quinine is the natural alkaloid extracted from the bark of the Cinchona tree and has been used against malaria for centuries. Its principal action is as a blood schizonticide: it concentrates in the parasite's digestive vacuole and, like chloroquine, interferes with heme handling to kill parasites in the erythrocytic (red blood cell) stage. It retains activity against many chloroquine-resistant strains, which preserves its role as a treatment agent. Option B is correct.
Option A: Option A is incorrect because quinine is not an 8-aminoquinoline and has no meaningful activity against dormant liver hypnozoites; that activity belongs to primaquine and tafenoquine.
Option C: Option C is incorrect because quinine is a small-molecule alkaloid, not a vaccine.
Option D: Option D is incorrect because quinine is a plant alkaloid, not a bacterially derived antibiotic, and its action is not ribosomal inhibition.
Option E: Option E is incorrect because quinine is not an endoperoxide (that describes artemisinins) and it acts on blood-stage parasites, not dormant liver forms.
9. Atovaquone-proguanil is a widely used malaria prophylaxis drug for travelers. It is described as a causal prophylactic, meaning it acts on the parasite in the liver. The drug combines atovaquone, which blocks the parasite mitochondrial electron transport chain (at cytochrome bc1), with proguanil. Which statement correctly describes its prophylactic action?
A) It eradicates dormant liver hypnozoites, providing radical cure and preventing all future relapses
B) It acts only on sexual-stage gametocytes and is therefore a transmission-blocking drug rather than a prophylactic
C) It must be started three weeks before travel because it acts slowly on red blood cell parasites only
D) It kills developing liver-stage (hepatic schizont) parasites before they are released into the blood, so it can be stopped soon after leaving the malaria-endemic area
E) It has no activity in humans and is used only as a laboratory reagent
ANSWER: D
Rationale:
Atovaquone-proguanil is a causal prophylactic: it kills the parasite during its developing liver (hepatic schizont) stage, before merozoites are released into the bloodstream to begin the symptomatic erythrocytic infection. Because it interrupts the parasite at this pre-erythrocytic step, it can be started shortly before travel and stopped about a week after leaving the endemic area, rather than continuing for four weeks as suppressive (blood-stage only) prophylactics require. Option D is correct.
Option A: Option A is incorrect because atovaquone-proguanil does not eliminate the dormant hypnozoites of vivax and ovale; only 8-aminoquinolines achieve that radical cure.
Option B: Option B is incorrect because it is an effective causal prophylactic acting on liver-stage parasites, not solely a gametocyte-targeting transmission blocker.
Option C: Option C is incorrect because its causal (liver-stage) action is precisely why it does not need to be started weeks in advance and is not a slow blood-stage-only agent.
Option E: Option E is incorrect because atovaquone-proguanil is an effective clinical antimalarial, not merely a laboratory reagent.
10. Malaria prophylaxis drugs fall into two groups based on where in the life cycle they act: causal prophylactics act on the liver stage, while suppressive prophylactics act only on the blood stage. This distinction has a direct practical consequence. Which statement correctly connects the mechanism to the clinical instruction?
A) A causal prophylactic kills liver-stage parasites and can be stopped about a week after leaving the endemic area, whereas a suppressive prophylactic acts only on blood-stage parasites and must be continued about four weeks after leaving
B) A suppressive prophylactic kills liver-stage parasites, so it can be stopped immediately on leaving the endemic area
C) Both causal and suppressive prophylactics eradicate dormant hypnozoites, so neither requires a terminal course of primaquine
D) A causal prophylactic must be continued for several months after travel because it acts slowly on dormant forms
E) The causal-versus-suppressive distinction is purely historical and has no effect on how long a traveler takes the drug
ANSWER: A
Rationale:
The practical reason the causal-versus-suppressive distinction matters is the duration of post-travel dosing. A causal prophylactic (for example atovaquone-proguanil) kills the parasite at the liver stage before blood infection is established, so any parasites the traveler acquired are stopped early and the drug can be discontinued about a week after leaving the endemic area. A suppressive prophylactic (for example chloroquine or mefloquine) acts only on blood-stage parasites, so it must be continued for about four weeks after departure to catch parasites that emerge from the liver after exposure. This is correct.
Option B: Option B is incorrect because suppressive prophylactics act on the blood stage, not the liver stage, and cannot be stopped immediately.
Option C: Option C is incorrect because neither causal nor suppressive prophylaxis eradicates hypnozoites; radical cure still requires an 8-aminoquinoline.
Option D: Option D is incorrect because the causal agent is stopped soon after travel, not continued for months.
Option E: Option E is incorrect because the distinction directly determines post-travel dosing duration.
11. Chloroquine resistance in Plasmodium falciparum is now widespread across most malaria-endemic regions of the world. A clinician is treating uncomplicated falciparum malaria acquired in a region where chloroquine-resistant strains predominate. Which prescribing decision is correct?
A) Use chloroquine monotherapy, because resistance affects only prophylaxis and not treatment
B) Use chloroquine combined with primaquine, because adding an 8-aminoquinoline restores chloroquine's blood-stage activity
C) Do not use chloroquine; treat with an artemisinin-based combination therapy (ACT), the recommended first-line treatment for chloroquine-resistant falciparum malaria
D) Double the chloroquine dose, because resistance can be overcome by higher blood concentrations
E) Withhold all antimalarials and observe, because chloroquine-resistant strains clear spontaneously
ANSWER: C
Rationale:
Where chloroquine-resistant Plasmodium falciparum predominates, chloroquine monotherapy will fail and must not be used; the recommended first-line treatment for uncomplicated chloroquine-resistant falciparum malaria is an artemisinin-based combination therapy (ACT). Option C is correct.
Option A: Option A is incorrect because chloroquine resistance affects treatment efficacy directly, not only prophylaxis.
Option B: Option B is incorrect because primaquine is an 8-aminoquinoline used for radical cure and transmission blocking; it does not restore chloroquine's blood-stage activity against resistant parasites.
Option D: Option D is incorrect because escalating the chloroquine dose does not reliably overcome resistance and adds toxicity; it is not an accepted strategy.
Option E: Option E is incorrect because falciparum malaria is potentially fatal and requires prompt effective treatment, never observation alone.
12. A patient being treated with quinine develops ringing in the ears (tinnitus), high-frequency hearing loss, headache, and nausea. These symptoms together form a characteristic toxicity syndrome associated with quinine and its stereoisomer quinidine. What is this syndrome called, and what is its clinical significance?
A) Blackwater fever, an immediate indication to stop the drug because it signals massive hemolysis
B) Cinchonism, a characteristic cluster of tinnitus, hearing loss, headache, and nausea that appears at therapeutic or mildly elevated levels and is usually not dose-limiting in short treatment courses
C) Cerebral malaria, indicating that the infection has progressed despite therapy
D) Serotonin syndrome, caused by quinine's potent inhibition of serotonin reuptake
E) Cinchonism, an indication that the patient has developed quinine resistance and should switch to chloroquine
ANSWER: B
Rationale:
The cluster of tinnitus, high-frequency hearing loss, headache, nausea, and visual disturbance produced by quinine and quinidine is called cinchonism (named for the Cinchona bark source of quinine). It typically appears at therapeutic or mildly supratherapeutic drug levels and, in the short courses used to treat malaria, is generally not dose-limiting and resolves when the drug is stopped. Option B correctly names the syndrome and its significance.
Option A: Option A is incorrect because blackwater fever refers to massive intravascular hemolysis with hemoglobinuria, a different and far more serious entity, not this symptom cluster.
Option C: Option C is incorrect because cerebral malaria is a complication of the infection itself, not a drug-toxicity syndrome.
Option D: Option D is incorrect because these symptoms are not serotonin syndrome and quinine is not acting as a serotonin reuptake inhibitor.
Option E: Option E is incorrect because cinchonism is a dose-related toxicity of the drug, not a marker of parasite resistance, and it does not indicate switching to chloroquine.
13. A patient is diagnosed with severe Plasmodium falciparum malaria (high parasite burden with signs of end-organ dysfunction) and requires intravenous antimalarial therapy. Which agent is the recommended first-line treatment for severe malaria, and what does it replace?
A) Intravenous chloroquine, replacing oral artemisinin combinations
B) Intravenous primaquine, replacing intravenous quinine
C) Oral atovaquone-proguanil, replacing all intravenous therapy
D) Intravenous doxycycline as monotherapy, replacing artemisinin derivatives
E) Intravenous artesunate, which has replaced intravenous quinine and quinidine as the first-line treatment for severe malaria
ANSWER: E
Rationale:
Intravenous artesunate is the recommended first-line treatment for severe malaria. It produces faster parasite clearance and improved survival compared with intravenous quinine, and it has replaced the older parenteral agents quinine and quinidine in this role. Option E is correct.
Option A: Option A is incorrect because chloroquine is not used for severe falciparum malaria, particularly given widespread resistance, and is not given intravenously for this purpose.
Option B: Option B is incorrect because primaquine is an 8-aminoquinoline used for radical cure and transmission blocking, not an intravenous treatment for severe acute malaria.
Option C: Option C is incorrect because severe malaria requires parenteral therapy; an oral agent such as atovaquone-proguanil is inappropriate for a patient who is severely ill and may not absorb oral drugs.
Option D: Option D is incorrect because doxycycline is used as a partner/companion agent, not as intravenous monotherapy for severe malaria.
14. A patient with Plasmodium vivax malaria is treated with chloroquine and the acute blood-stage illness resolves completely. Several weeks later the patient relapses. Assuming the patient was not re-exposed, what explains why chloroquine alone did not prevent this relapse?
A) Chloroquine was dosed too low; a higher dose of chloroquine alone would have prevented relapse
B) Chloroquine selects for resistant gametocytes that re-enter the bloodstream weeks later
C) Chloroquine acts only on the liver stage and leaves blood-stage parasites untreated
D) Chloroquine kills blood-stage parasites but has no activity against the dormant liver hypnozoites of P. vivax, which reactivate later unless an 8-aminoquinoline is added for radical cure
E) Chloroquine cures relapse on its own, so the recurrence must represent a new infection
ANSWER: D
Rationale:
This question applies the hypnozoite concept established earlier. Chloroquine is a blood schizonticide: it clears the erythrocytic-stage parasites and resolves the acute illness, but it has no activity against the dormant liver hypnozoites that P. vivax (and P. ovale) form. Those hypnozoites persist in the liver and reactivate weeks to months later, producing relapse, unless an 8-aminoquinoline (primaquine or tafenoquine) is added to achieve radical cure. Option D is correct.
Option A: Option A is incorrect because the failure is not a matter of chloroquine dose; chloroquine simply cannot reach the hypnozoite reservoir at any dose.
Option B: Option B is incorrect because relapse is driven by reactivating liver hypnozoites, not by resistant gametocytes.
Option C: Option C is incorrect because it inverts chloroquine's pharmacology — chloroquine acts on the blood stage, not the liver stage.
Option E: Option E is incorrect because, with no re-exposure, the recurrence is relapse from dormant liver forms, not a new infection.
15. When quinine is used to treat malaria, it is not given alone — it is routinely paired with a companion antibiotic such as doxycycline or clindamycin for a 7-day course. Which statement best explains this practice?
A) Quinine has a narrow margin between effective and toxic doses and incomplete efficacy alone, so a companion antibiotic (doxycycline or clindamycin) is added to improve cure rates and reduce selection of resistance
B) The companion antibiotic is added only to treat unrelated bacterial coinfections and has no role in the malaria cure
C) Doxycycline and clindamycin are themselves rapidly acting blood schizonticides that cure malaria within hours, making quinine unnecessary
D) The combination is used because quinine eradicates liver hypnozoites and the antibiotic prevents the resulting hemolysis
E) The antibiotic is added solely to mask the tinnitus of cinchonism and has no antiparasitic purpose
ANSWER: A
Rationale:
Quinine has a narrow therapeutic index (a small margin between therapeutic and toxic concentrations) and, used alone, has limited efficacy and a risk of selecting for resistance. Pairing it with a companion antibiotic — doxycycline or clindamycin — over a 7-day course improves cure rates and reduces resistance selection. Option A is correct.
Option B: Option B is incorrect because the antibiotic is an integral part of the antimalarial regimen, not merely treatment for a separate bacterial infection.
Option C: Option C is incorrect because doxycycline and clindamycin are slow-acting antimalarials and cannot rapidly cure malaria on their own; quinine provides the rapid blood-stage activity.
Option D: Option D is incorrect because quinine does not eradicate liver hypnozoites (that requires an 8-aminoquinoline), and the antibiotic is not added to prevent hemolysis.
Option E: Option E is incorrect because the companion antibiotic has a genuine antiparasitic role and is not given to mask cinchonism.
16. Beyond its role in eradicating liver hypnozoites, primaquine has a second distinct use in malaria control. A single low dose of primaquine may be added to falciparum treatment specifically to interrupt the spread of malaria to others in the community. Which property of primaquine explains this transmission-blocking use?
A) Primaquine sterilizes the Anopheles mosquito so it can no longer bite
B) Primaquine prevents mosquitoes from acquiring the infection by repelling them from treated patients
C) Primaquine boosts host antibody production, generating herd immunity within days
D) Primaquine eliminates dormant liver hypnozoites in the mosquito, breaking the cycle
E) Primaquine is gametocytocidal — it kills the mature sexual-stage gametocytes of P. falciparum in the patient's blood, so a feeding mosquito does not pick up viable parasites
ANSWER: E
Rationale:
Malaria is transmitted when a mosquito ingests mature sexual-stage parasites (gametocytes) from an infected person's blood. Primaquine is gametocytocidal against mature Plasmodium falciparum gametocytes, so a single low dose added to treatment clears these transmissible forms from the patient's blood; a mosquito that subsequently feeds does not acquire viable parasites, interrupting onward transmission. Option E is correct.
Option A: Option A is incorrect because primaquine does not sterilize mosquitoes; it acts on parasites in the human host.
Option B: Option B is incorrect because primaquine is not a mosquito repellent.
Option C: Option C is incorrect because primaquine does not work by stimulating host antibody production or generating herd immunity.
Option D: Option D is incorrect because hypnozoites are a human liver-stage phenomenon, not a mosquito stage, and the transmission-blocking effect is due to gametocyte killing in the patient's blood.
17. A patient is diagnosed with Plasmodium vivax malaria. Using the concepts established earlier in this set about hypnozoites and the difference between blood-stage and liver-stage drugs, which treatment plan provides complete therapy and the best chance of preventing relapse (after appropriate pre-treatment testing)?
A) A blood schizonticide alone, because clearing the bloodstream parasites is sufficient to prevent vivax relapse
B) An 8-aminoquinoline (primaquine) alone, because it covers both the blood stage and the liver stage in vivax
C) A blood schizonticide to clear the acute erythrocytic infection PLUS a terminal course of an 8-aminoquinoline (primaquine or tafenoquine) to eradicate dormant liver hypnozoites
D) A single dose of artemisinin with no partner drug and no liver-stage agent
E) Long-term suppressive chloroquine indefinitely, because relapse cannot otherwise be addressed
ANSWER: C
Rationale:
This bridge question applies two earlier concepts: vivax forms dormant liver hypnozoites, and blood-stage drugs do not reach them. Complete therapy therefore has two components — a blood schizonticide (for example chloroquine where the strain is sensitive, or an ACT) to clear the acute erythrocytic infection, plus a terminal 8-aminoquinoline course (primaquine or tafenoquine, after G6PD testing) to eradicate the hypnozoites and prevent relapse (radical cure). Option C is correct.
Option A: Option A is incorrect because a blood schizonticide alone leaves the hypnozoite reservoir intact and relapse follows.
Option B: Option B is incorrect because primaquine is not a reliable blood schizonticide for the acute illness; it is added for radical cure, not used alone to treat acute vivax.
Option D: Option D is incorrect because a single dose of artemisinin without a partner drug is inadequate treatment and provides no liver-stage (anti-relapse) activity.
Option E: Option E is incorrect because indefinite suppressive chloroquine does not eradicate hypnozoites and is not the correct way to prevent relapse; a terminal 8-aminoquinoline is.
18. Earlier in this set you learned that chloroquine works by accumulating in the parasite's acidic digestive vacuole and blocking heme detoxification there. Chloroquine resistance in P. falciparum is caused mainly by a mutation (K76T) in a transporter protein called PfCRT located in the digestive vacuole membrane. Using the mechanism of chloroquine action, which explanation of how this mutation causes resistance is correct?
A) The mutant transporter pumps chloroquine out of the digestive vacuole, lowering the drug concentration at its site of action so heme detoxification is no longer blocked
B) The mutant transporter destroys free heme directly, so chloroquine has nothing to bind
C) The mutation makes the parasite stop digesting hemoglobin, so no digestive vacuole forms at all
D) The mutation converts chloroquine into an active 8-aminoquinoline that the parasite then excretes
E) The mutation increases chloroquine uptake into the vacuole, so the drug becomes paradoxically more effective
ANSWER: A
Rationale:
This bridge question applies the chloroquine mechanism (the drug must accumulate in the digestive vacuole to block heme polymerization). The K76T mutation in PfCRT produces a transporter that exports chloroquine out of the digestive vacuole, so the drug no longer reaches the high local concentration required to bind free heme and block its detoxification; the parasite survives. Option A correctly links the transporter change to reduced drug concentration at the site of action.
Option B: Option B is incorrect because the transporter does not destroy heme; it relocates the drug.
Option C: Option C is incorrect because resistant parasites still digest hemoglobin and form a digestive vacuole; they simply expel the drug from it.
Option D: Option D is incorrect because the mutation does not chemically convert chloroquine into another drug class.
Option E: Option E is incorrect because it inverts the mechanism — resistance results from reduced, not increased, drug accumulation in the vacuole.
19. The toxicity profiles introduced earlier distinguish the antimalarials from one another. A patient is taking hydroxychloroquine long-term (for a non-malarial inflammatory condition). Which monitoring is specifically indicated because of a characteristic toxicity of the 4-aminoquinolines chloroquine and hydroxychloroquine with prolonged use?
A) Periodic G6PD enzyme testing, because these drugs cause cumulative oxidative hemolysis
B) Periodic neuropsychiatric screening, because these drugs characteristically cause psychosis with long-term use
C) Periodic ophthalmologic (retinal) examination, because chloroquine and hydroxychloroquine can cause cumulative, potentially irreversible retinopathy
D) Periodic audiometry, because these drugs cause the progressive hearing loss of cinchonism with chronic use
E) No monitoring is needed, because chloroquine and hydroxychloroquine have no significant long-term toxicity
ANSWER: C
Rationale:
This bridge question applies the toxicity concept. The characteristic long-term toxicity of the 4-aminoquinolines chloroquine and hydroxychloroquine is retinopathy: cumulative retinal damage that can be irreversible and threaten vision, which is why patients on prolonged therapy undergo periodic ophthalmologic (retinal) screening, with attention to cumulative dose and duration. Option C is correct.
Option A: Option A is incorrect because dose-dependent oxidative hemolysis in G6PD deficiency is the hallmark of the 8-aminoquinolines (primaquine, tafenoquine), not the long-term concern that drives chloroquine/hydroxychloroquine monitoring.
Option B: Option B is incorrect because the prominent neuropsychiatric toxicity belongs to mefloquine.
Option D: Option D is incorrect because progressive hearing loss is part of cinchonism from quinine and quinidine, not the monitored long-term toxicity of hydroxychloroquine.
Option E: Option E is incorrect because these drugs do have a clinically important long-term toxicity — retinopathy — that requires monitoring.
20. Recall from earlier in this set that an ACT combines a fast-acting artemisinin with a longer-acting partner drug. In parts of Southeast Asia, parasites show artemisinin partial resistance, recognized as "delayed clearance" (parasites are cleared more slowly than normal). Using the two-drug logic of the ACT, which statement best explains when this delayed clearance translates into actual treatment failure?
A) Delayed clearance always causes immediate treatment failure regardless of the partner drug, because the artemisinin component is the only one that matters
B) Artemisinin partial resistance alone often does not cause clinical failure, but when resistance to the longer-acting partner drug also develops, the combination loses its backup and clinical treatment failure occurs
C) Delayed clearance improves cure rates, because slower killing exposes parasites to the drug for longer
D) Treatment failure depends only on the patient's immune system and is unrelated to partner-drug resistance
E) Partner-drug resistance protects against failure by compensating for the weakened artemisinin
ANSWER: B
Rationale:
This bridge question applies the ACT design concept. The artemisinin rapidly reduces parasite burden while the longer-acting partner drug clears the remainder; the partner drug is the safety net. Artemisinin partial resistance (delayed clearance) alone frequently does not produce outright clinical failure, because the partner drug still finishes the job. Failure rates climb when resistance to the partner drug develops as well: the artemisinin is weakened and its backup is gone, so the combination fails. This is correct.
Option A: Option A is incorrect because partial artemisinin resistance does not invariably cause failure when the partner drug remains effective.
Option C: Option C is incorrect because delayed clearance reflects reduced drug effect, not improved cure.
Option D: Option D is incorrect because partner-drug resistance is precisely what drives ACT failure in this setting, so failure is not independent of it.
Option E: Option E is incorrect because partner-drug resistance worsens, rather than compensates for, the loss of artemisinin activity.
21. Earlier you learned why a G6PD level is checked before an 8-aminoquinoline. A patient with confirmed P. vivax malaria is found on quantitative testing to be G6PD deficient. The acute blood-stage illness has been treated. Applying the link between G6PD status and 8-aminoquinoline hemolysis, which course of action is most appropriate for relapse prevention?
A) Give standard full-dose daily primaquine immediately, because G6PD status does not influence 8-aminoquinoline safety
B) Give a double dose of primaquine, because G6PD-deficient red cells require more drug to respond
C) Give tafenoquine at full single dose without concern, because tafenoquine is safe in G6PD deficiency
D) Recognize that standard 8-aminoquinoline dosing risks severe hemolysis in this patient, and individualize the decision — for example a modified (such as intermittent weekly) primaquine regimen under supervision, with monitoring, rather than routine standard-dose radical cure
E) Abandon any attempt at relapse prevention permanently and never reassess
ANSWER: D
Rationale:
This bridge question applies the G6PD-hemolysis link. In a G6PD-deficient patient, standard 8-aminoquinoline dosing carries a real risk of severe oxidative hemolysis, so the radical-cure decision must be individualized rather than executed as routine standard-dose therapy. An accepted approach is a modified, supervised regimen (for example intermittent weekly primaquine with hemoglobin monitoring) weighing relapse risk against hemolysis risk. Option D captures this individualized, risk-weighted approach.
Option A: Option A is incorrect because G6PD status critically affects 8-aminoquinoline safety; standard full-dose primaquine could cause dangerous hemolysis.
Option B: Option B is incorrect and dangerous because increasing the dose increases oxidative hemolysis, not efficacy of red-cell defense.
Option C: Option C is incorrect because tafenoquine, a long-acting 8-aminoquinoline, is actually contraindicated in G6PD deficiency precisely because its prolonged action makes hemolysis worse and non-reversible; it is not a safe substitute.
Option E: Option E is incorrect because relapse prevention is not simply abandoned forever; the decision is individualized with monitoring, not discarded without reassessment.
22. Recall the neuropsychiatric profile of mefloquine introduced earlier. A traveler with no psychiatric contraindication chooses weekly mefloquine for prophylaxis before a trip to a remote area. Applying what you know about mefloquine's adverse effects, why is mefloquine typically started 2 to 3 weeks before departure rather than just before travel?
A) Because mefloquine has no antimalarial activity until it has accumulated in the body for a full 3 weeks
B) Because the early start is required to deplete dormant liver hypnozoites before exposure begins
C) Because mefloquine causes oxidative hemolysis that must first be monitored with serial G6PD testing over several weeks
D) Because mefloquine must be titrated to a target QT interval before a traveler can safely depart
E) Because starting early lets any neuropsychiatric intolerance — such as disturbing dreams, anxiety, or mood change — emerge while the traveler is still home and can switch to a different drug before reaching a remote destination
ANSWER: E
Rationale:
This bridge question applies the mefloquine neuropsychiatric concept. Because mefloquine can cause vivid or disturbing dreams, anxiety, mood changes, and other neuropsychiatric effects in a meaningful minority of users, prophylaxis is begun 2 to 3 weeks before departure: this lead-in lets intolerance surface while the traveler is still at home and able to change to an alternative agent, rather than discovering the problem in a remote location far from care. This is correct.
Option A: Option A is incorrect because the early start is about detecting tolerability, not because mefloquine lacks activity until it accumulates for three weeks.
Option B: Option B is incorrect because mefloquine does not eliminate liver hypnozoites; that is the role of the 8-aminoquinolines, and it is not the reason for the lead-in.
Option C: Option C is incorrect because oxidative hemolysis and G6PD testing pertain to the 8-aminoquinolines, not mefloquine.
Option D: Option D is incorrect because mefloquine is not titrated to a QT-interval target before travel; pronounced QT effects are characteristic of quinine and quinidine, and that is not the reason for the early start.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.